Company Update (NASDAQ:AMGN): Platelet BioGenesis Wins Amgen Golden Ticket For LabCentral

[PR Newswire] – CAMBRIDGE, Mass., May 9, 2016 /PRNewswire/ — Amgen (AMGN) and LabCentral announced today that Platelet BioGenesis is an Amgen’s 2016 winner of the highly competitive Golden Ticket award, which underwrites the cost of a lab bench for a Platelet BioGenesis scientist in LabCentral’s open lab for one year. LabCentral is an innovative, shared laboratory space designed as a launchpad for premier high-impact life-sciences and biotech startups. As one of LabCentral’s platinum sponsors, Amgen can nominate up to two early-stage companies to take up residence in LabCentral’s Kendall Square facilities in Cambridge, Massachusetts. Read more on this. Amgen Inc. (AMGN) , valued at $116.84B, opened at $153.70. During today’s session, AMGN traded between $153.02 to $155.80 and has traded between $130.09 and $181.81 over the past year. Amgen (AMGN) shares are currently priced at 13.76x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -1.94x earnings multiple for the same period. And for income investors, the company pays shareholders $4.00 per share annually in dividends, yielding 2.61%. Consensus earnings for the current quarter by the 19 sell-side analysts covering the stock is an estimate of $2.76 per share, which would be $0.19 better than the year-ago quarter and a $0.03 sequential increase. The full-year EPS estimate is $11.13 which would be a $0.75 better than last year’s full-year earnings. The quarterly earnings estimate is predicated on a consensus revenue forecast of $5.59 Billion. If reported, that would be a 4.10% increase over the year-ago quarter. In terms of ratings, Citigroup Initiated AMGN at Neutral (Feb 25, 2016). Previously, Credit Suisse Initiated AMGN at to Outperform. The average price target for AMGN shares by the analysts covering the stock is $182.06, which is 18.45% above where the stock opened this morning. See more in (NASDAQ:AMGN) Similar Articles: Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90 Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen To Participate In The 2016 World Medical Innovation Forum™ On Cancer Stock Update: Amgen Inc (NASDAQ:AMGN) – Unilife and Amgen Enter Strategic Collaboration for Injectable Drug Delivery Systems